Lung cancer remains the leading cause of cancer-related death in the United States; approximately 85% of lung cancers are non-small cell lung cancer (NSCLC), with ~530K cases in the 7MM. The main subtypes of NSCLC are adenocarcinoma (~57%), squamous cell carcinoma (~26%), and large cell carcinoma (~2%). Despite advances in chemotherapy, targeted therapies, and immunotherapy, the high prevalence of NSCLC continues to present a significant challenge in treatment.
ADCs in lung cancer represent an exciting advancement in cancer therapy, combining the precision of monoclonal antibodies with the potency of cytotoxic drugs to deliver targeted treatment directly to cancer...
